ARCHIVES

FDA News: FDA Approved A Supplemental New Drug Application For Nexavar Tablets (Sorafenib) For The Treatment Of Patients With Locally Recurrent Or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory To Radioactive Iodine Treatment.

This article is from The Cancer Letter archive.

Vol. 39 No. 45 | December 17, 2013

Download PDF Visit The Full Archive

Related Articles

Pediatric Rule Makes FDA Consider Defining Tumors By Molecular Target.

August 31, 2001

Therapeutic Modalities Improve Patient Quality of Life In Trials

February 27, 2004

FDA Breakthrough Designation Granted to Pfizer’s Palbociclib

April 26, 2013

William Nelson Named Cancer Center Director At Johns Hopkins.

November 7, 2008

Field Studies Chief Leave For Job with Upton; Sibal Named DCCP Acting Deputy

October 27, 1978

In Brief: House Budget Committee Proposes 5% Cut To NIH In FY96; Steady Reductions Expected

March 24, 1995